Modified Screening Questionnaire for Psoriatic Arthritis in Adults With Psoriasis
Tests a modified screening questionnaire for joint disease in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Modifying PEST for Psoriatic Arthritis Screening
Key facts
- Where
- Barrie, Calgary, Edmonton, Fredericton, Greater Sudbury, Hamilton, Kelowna, London, Markham, Montreal, Ottawa, Québec, Richmond Hill, Saskatoon, Ste-Foy, Stoney Creek, Surrey, Toronto, Verdun, Waterloo, and Winnipeg, CanadaSee the 21 sites
Where in Canada
- BarrieBarrie, CanadaTaking people
- CalgaryCalgary, CanadaTaking people
- EdmontonEdmonton, CanadaTaking people
- FrederictonFredericton, CanadaTaking people
- Greater SudburyGreater Sudbury, CanadaTaking people
- HamiltonHamilton, CanadaTaking people
- KelownaKelowna, CanadaTaking people
- LondonLondon, CanadaTaking people
- MarkhamMarkham, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- OttawaOttawa, CanadaTaking people
- QuébecQuébec, CanadaTaking people
- Richmond HillRichmond Hill, CanadaTaking people
- SaskatoonSaskatoon, CanadaTaking people
- Ste-FoySte-Foy, CanadaTaking people
- Stoney CreekStoney Creek, CanadaTaking people
- SurreySurrey, CanadaTaking people
- TorontoToronto, CanadaTaking people
- VerdunVerdun, CanadaTaking people
- WaterlooWaterloo, CanadaTaking people
- WinnipegWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06382051
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.Read full original descriptionShow less
A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Inclusion: Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment; Adult patients at the time of informed consent signature; Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions; Residents of Canada.
Exclusion: Patients who have previously screened positive for PsA through PEST; Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment; Patients who have been diagnosed with PsA; Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis).